Neurology @Point of Care Podcasts

In this episode, our faculty looks at the latest treatments for multiple sclerosis—the newest sphingosine-1-phosphate receptor modulators. What is their mechanism of action? Which patients would benefit from them, and how are side effects and toxicities managed with these latest treatment options? Visit www.morningcommutepodcast.com/ms8 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

With the many treatments now available for the treatment of multiple sclerosis (MS), our faculty reviews this impressive therapeutic landscape and discusses how to choose the best ones for the individual MS patient. Visit www.morningcommutepodcast.com/ms7 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

Are there issues with getting the Covid-19 vaccine and boosters for patients with MS who are on disease-modifying therapies? In this podcast our faculty discuss the safety and efficacy of the vaccines, timing with disease-modifying therapies, and monoclonal antibodies for prevention and treatment.

What is the efficacy of Covid-19 vaccines for multiple sclerosis patients? In this podcast our faculty discuss vaccine safety, how vaccines are affected by disease modifying drugs, and the importance of the vaccines and boosters for this patient population.

In this podcast our faculty discuss new and emerging treatments for ALS, as well as managing some of the more debilitating symptoms of the disease. Visit www.morningcommutepodcast.com/als1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

Is amyloid the right target for new Alzheimer's disease therapies? Will any of these therapies, if they win approval, advance the treatment of Alzheimer's disease? Our faculty explores these and other questions. Visit www.morningcommutepodcast.com/ad2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

Are there viable blood tests on the horizon to make diagnosis, and particularly early diagnosis, of Alzheimer's disease possible? Our faculty takes a look at this excited field that may also enable development of better therapeutics for the disease. Visit www.morningcommutepodcast.com/ad1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

Visit journalclubpodcasts.com/als to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts discuss several papers showing how the virus may affect ALS patients as well as what they are seeing in their clinics.

Visit http://morningcommutepodcast.com/ms6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss where we are now and what the future holds as new MS therapies emerge. For MS, has the era of true personalized medicine arrived?

Visit http://morningcommutepodcast.com/ms5 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss the existing and new sphingosine-1-phosphate receptor (S1PR) modulator therapies and current ongoing trials. Particularly, they will delve into what can and cannot be presumed about comparative efficacy given the absence of head-to-head trials.

Visit http://morningcommutepodcast.com/ms4 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss the current evidence for disease-modifying therapies (DMTs) in patients with active secondary progressive MS. How is SPMS diagnosed and how does it differ from relapsing-remitting MS? Moreover, are the treatments for SPMS effective for RRMS?

Visit http://morningcommutepodcast.com/ms3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode – Alike, But Not Alike, our faculty will discuss how newly available diroximel fumarate (DRF) and monomethyl fumarate (MMF) compare with dimethyl fumarate (DMF). How are they alike? How do they differ? Is MMF a drug equivalent to DMF?

Visit http://morningcommutepodcast.com/ms2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode – Switching Tracks in MS, Timing and Direction—our faculty will discuss current perspectives on treatment escalation and lateral switches in MS patient care. They will also discuss how to assess clinical response and when a switch is warranted.

Visit http://morningcommutepodcast.com/ms1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In our first episode – Crystal Gazing in MS, our faculty will discuss establishing the MS diagnosis, and prognostication – namely, treatment initiation timing and first line treatment selection. What forms the basis for this? How do clinicians determine an MS patient's long-term or short-term prognosis? Does it take a crystal ball?

Visit journalclubpodcasts.com/parkinsonsdisease to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts discuss a paper published in the Journal of Clinical Medicine that looked at the impact of Covid-19 on patients with Parkinson's disease—physically, emotionally, and how they are keeping up with their treatments